These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28585539)

  • 1. IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours.
    Seo H; Jeon I; Kim BS; Park M; Bae EA; Song B; Koh CH; Shin KS; Kim IK; Choi K; Oh T; Min J; Min BS; Han YD; Kang SJ; Shin SJ; Chung Y; Kang CY
    Nat Commun; 2017 Jun; 8():15776. PubMed ID: 28585539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors.
    Seo H; Kim BS; Bae EA; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Immunol Res; 2018 Jun; 6(6):685-695. PubMed ID: 29615398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
    Cheng WF; Hung CF; Lee CN; Su YN; Chang MC; He L; Wu TC; Chen CA; Hsieh CY
    Eur J Immunol; 2004 Jul; 34(7):1892-900. PubMed ID: 15214037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The functional potency of natural killer cells in response to IL-2/IL-15/IL-21 stimulation is limited by a concurrent upregulation of Tim-3 in bladder cancer.
    Zhang W; Feng H; Chen Q; Lu X; Ge J
    Exp Cell Res; 2018 Nov; 372(2):92-98. PubMed ID: 30243902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro.
    Kijima M; Saio M; Oyang GF; Suwa T; Miyauchi R; Kojima Y; Imai H; Nakagawa J; Nonaka K; Umemura N; Nishimura T; Takami T
    Int J Oncol; 2005 Mar; 26(3):679-84. PubMed ID: 15703823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours.
    Indrová M; Símová J; Bieblová J; Bubeník J; Reinis M
    Oncol Rep; 2011 Jan; 25(1):281-8. PubMed ID: 21109988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.
    da Silva IP; Gallois A; Jimenez-Baranda S; Khan S; Anderson AC; Kuchroo VK; Osman I; Bhardwaj N
    Cancer Immunol Res; 2014 May; 2(5):410-22. PubMed ID: 24795354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
    Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
    J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New avenues for melanoma immunotherapy: Natural Killer cells?
    Cristiani CM; Garofalo C; Passacatini LC; Carbone E
    Scand J Immunol; 2020 Apr; 91(4):e12861. PubMed ID: 31879979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis.
    Ma D; Niederkorn JY
    Immunology; 1995 Oct; 86(2):263-9. PubMed ID: 7490128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines.
    Reinis M; Stepanek I; Simova J; Bieblova J; Pribylova H; Indrova M; Bubenik J
    Int J Oncol; 2010 Mar; 36(3):545-51. PubMed ID: 20126973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response.
    Yajima T; Nishimura H; Wajjwalku W; Harada M; Kuwano H; Yoshikai Y
    Int J Cancer; 2002 Jun; 99(4):573-8. PubMed ID: 11992548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cell expression of Tim-3: First impressions matter.
    So EC; Khaladj-Ghom A; Ji Y; Amin J; Song Y; Burch E; Zhou H; Sun H; Chen S; Bentzen S; Hertzano R; Zhang X; Strome SE
    Immunobiology; 2019 May; 224(3):362-370. PubMed ID: 30876792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours.
    Reinis M; Símová J; Indrová M; Bieblová J; Pribylová H; Moravcová S; Jandlová T; Bubeník J
    Int J Oncol; 2007 Apr; 30(4):1011-7. PubMed ID: 17332942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.
    Liu Y; Cheng Y; Xu Y; Wang Z; Du X; Li C; Peng J; Gao L; Liang X; Ma C
    Oncogene; 2017 Nov; 36(44):6143-6153. PubMed ID: 28692048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells.
    Goding SR; Yu S; Bailey LM; Lotze MT; Basse PH
    Clin Immunol; 2017 Apr; 177():76-86. PubMed ID: 27377534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model.
    Ma D; Luyten GP; Luider TM; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):435-41. PubMed ID: 7843912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors.
    Ardolino M; Azimi CS; Iannello A; Trevino TN; Horan L; Zhang L; Deng W; Ring AM; Fischer S; Garcia KC; Raulet DH
    J Clin Invest; 2014 Nov; 124(11):4781-94. PubMed ID: 25329698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of innate immunity in the tumor microenvironment.
    Gonzalez-Gugel E; Saxena M; Bhardwaj N
    Cancer Immunol Immunother; 2016 Oct; 65(10):1261-8. PubMed ID: 27344341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.